Lerner, A Martin, Ariza, Maria E, Williams, Marshall et al. · PloS one · 2012 · DOI
This study looked at a small group of ME/CFS patients to see if they had a specific pattern of antibodies (immune proteins) related to Epstein-Barr virus (EBV), a common virus that causes mono. The researchers found that most of these patients had high levels of antibodies against EBV proteins, and when they treated these patients with an antiviral medication for over a year, the patients improved. This suggests that EBV might be involved in ME/CFS for some patients, and a blood test might help identify them.
This study provides preliminary evidence for a biological marker that could identify and distinguish a subset of ME/CFS patients with ongoing EBV activation, potentially enabling targeted antiviral treatment. If validated in larger cohorts, such a diagnostic panel could improve disease stratification and guide personalized therapeutic approaches for patients who may benefit from antivirals.
This study does not prove that EBV causes ME/CFS broadly, nor does it establish that antiviral treatment is universally effective for all ME/CFS patients. The improvement observed cannot be separated from placebo effects or natural recovery, and the very small sample size (n=6) means findings may not reflect the larger ME/CFS population. Correlation between elevated antibodies and symptom improvement does not prove causation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →